Continuous dopaminergic stimulation - From theory to clinical practice

被引:33
作者
Antonini, Angelo [1 ]
机构
[1] Parkinson Inst, Ist Clin Perfezionamento, Milan, Italy
关键词
Parkinson's disease; apomorphine; STN-DBS; levdopa;
D O I
10.1016/j.parkreldis.2007.06.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Patients with advanced Parkinson's disease (PD) experience worsening motor fluctuations and dyskinesia. Management options include deep brain stimulation of the subthalamic nucleus (STN-DBS), subcutaneous apomorphine (in combination with oral levodopa) or continuous duodenal levodopa administration. We have used all three therapies at our clinic in Milan and report our experience. Apomorphine infusion reduced daily off time but did not improve dyskinesia; long-term treatment was associated with impulse control disorders. STN-DBS provided motor benefit, but was associated with behavioural changes including attempted suicide. Duodenal levodopa produced significant clinical benefit without behavioural changes and allowed patients to discontinue all other PD medications. Duodenal levodopa should be considered in PD patients with advanced disease. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:S24 / S28
页数:5
相关论文
共 25 条
[1]   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].
Ahlskog, JE ;
Muenter, MD .
MOVEMENT DISORDERS, 2001, 16 (03) :448-458
[2]  
Antonini A, 2006, MOVEMENT DISORD, V21, pS550
[3]   Suicide after successful deep brain stimulation for movement disorders [J].
Burkhard, PR ;
Vingerhoets, FJG ;
Berney, A ;
Bogousslavsky, J ;
Villemure, JG ;
Ghika, J .
NEUROLOGY, 2004, 63 (11) :2170-2172
[4]   Impact of the motor complications of Parkinson's disease on the quality of life [J].
Chapuis, S ;
Ouchchane, L ;
Metz, O ;
Gerbaud, L ;
Durif, F .
MOVEMENT DISORDERS, 2005, 20 (02) :224-230
[5]   The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease [J].
Chase, TN .
DRUGS, 1998, 55 (Suppl 1) :1-9
[6]   Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus [J].
De Gaspari, D ;
Siri, C ;
Landi, A ;
Cilia, R ;
Bonetti, A ;
Natuzzi, F ;
Morgante, L ;
Mariani, CB ;
Sganzerla, E ;
Pezzoli, G ;
Antonini, A .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (04) :450-453
[7]  
Defer GL, 1999, MOVEMENT DISORD, V14, P572, DOI 10.1002/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO
[8]  
2-C
[9]   Subcutaneous apomorphine - An evidence-based review of its use in Parkinson's disease [J].
Deleu, D ;
Hanssens, Y ;
Northway, MG .
DRUGS & AGING, 2004, 21 (11) :687-709
[10]   Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease [J].
Di Rosa, AE ;
Epifanio, A ;
Antonini, A ;
Stocchi, F ;
Martino, G ;
Di Blasi, L ;
Tetto, A ;
Basile, G ;
Imbesi, D ;
La Spina, P ;
Di Raimondo, G ;
Morgante, L .
NEUROLOGICAL SCIENCES, 2003, 24 (03) :174-175